Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.

Tekin MD, Erdoğan AP, Şahbazlar M, Faraşat M, Pehlivan FS, Ekinci F

Open source

DOI
10.1186/s12894-026-02264-5
Published
2026 Jul 20
Container
BMC urology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12894-026-02264-5,
  title = {Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.},
  author = {Tekin MD and Erdoğan AP and Şahbazlar M and Faraşat M and Pehlivan FS and Ekinci F},
  year = {2026},
  journal = {BMC urology},
  doi = {10.1186/s12894-026-02264-5},
  url = {https://doi.org/10.1186/s12894-026-02264-5}
}

RIS

TY  - JOUR
TI  - Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.
AU  - Tekin MD
AU  - Erdoğan AP
AU  - Şahbazlar M
AU  - Faraşat M
AU  - Pehlivan FS
AU  - Ekinci F
PY  - 2026
JO  - BMC urology
DO  - 10.1186/s12894-026-02264-5
UR  - https://doi.org/10.1186/s12894-026-02264-5
ER  - 

APA

MD, T., AP, E., M, Ş., M, F., FS, P., & F, E. (2026). Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.. BMC urology. https://doi.org/10.1186/s12894-026-02264-5

Source records